XERS Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. (XERS) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $722.5K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Hecht Beth | See Remarks | Sell 10b5-1 | 16,666 | $8.49 | $141.4K | 1,127,796 −1.5% of holding | |
| McCulloch Kevin | See Remarks | Sell 10b5-1 | 15,000 | $8.49 | $127.3K | 1,639,208 −0.9% of holding | |
| Pieper Steven | See Remarks | Sell 10b5-1 | 5,000 | $8.50 | $42.5K | 1,356,053 −0.4% of holding | |
| Pieper Steven | See Remarks | Sell 10b5-1 | 5,000 | $8.50 | $42.5K | 1,361,053 −0.4% of holding | |
| Hecht Beth | See Remarks | Sell 10b5-1 | 16,666 | $8.01 | $133.6K | 1,144,462 −1.4% of holding | |
| McCulloch Kevin | See Remarks | Sell 10b5-1 | 15,000 | $8.02 | $120.2K | 1,676,126 −0.9% of holding | |
| Pieper Steven | See Remarks | Sell 10b5-1 | 27,600 | $8.52 | $235.3K | 1,366,053 −2% of holding | |
| Pieper Steven | See Remarks | Sell 10b5-1 | 17,400 | $8.50 | $147.9K | 1,393,653 −1.2% of holding | |
| McCulloch Kevin | See Remarks | Sell 10b5-1 | 90,000 | $8.03 | $722.5K | 1,691,126 −5.1% of holding | |
| Hecht Beth | See Remarks | Sell 10b5-1 | 16,666 | $8.03 | $133.9K | 1,161,128 −1.4% of holding | |
| HALKUFF DAWN | Director | Sell 10b5-1 | 20,000 | $6.09 | $121.9K | 95,000 −17.4% of holding | |
| BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | Sell 10b5-1 | 16,000 | $6.09 | $97.5K | 126,500 −11.2% of holding | |
| JOHNSON JOHN | Director | Sell 10b5-1 | 15,000 | $6.09 | $91.4K | 683,083 −2.1% of holding | |
| PERSKY MARLA | Director | Sell 10b5-1 | 15,500 | $5.90 | $91.4K | 126,500 −10.9% of holding | |
| Hecht Beth | See Remarks | Sell 10b5-1 | 16,667 | $6.06 | $101.0K | 1,176,506 −1.4% of holding | |
| Hecht Beth | See Remarks | Sell 10b5-1 | 16,667 | $6.23 | $103.8K | 1,193,173 −1.4% of holding | |
| Hecht Beth | See Remarks | Sell 10b5-1 | 16,667 | $5.99 | $99.9K | 1,209,840 −1.4% of holding | |
| Brady James Aloysius | Director | Sell 10b5-1 | 10,834 | $5.54 | $60.0K | 89,166 −10.8% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.